Get the Stockscreener App
3.28
0.61%
-0.02
After Hours:
3.27
-0.010
-0.30%
Arbutus Biopharma Corp stock is traded at $3.28, with a volume of 730.30K.
It is down -0.61% in the last 24 hours and up +6.15% over the past month.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
See More
Previous Close:
$3.30
Open:
$3.29
24h Volume:
730.30K
Relative Volume:
0.93
Market Cap:
$628.21M
Revenue:
$12.99M
Net Income/Loss:
$-74.39M
P/E Ratio:
-7.4545
EPS:
-0.44
Net Cash Flow:
$-78.92M
1W Performance:
+1.23%
1M Performance:
+6.15%
6M Performance:
-1.50%
1Y Performance:
-13.00%
1-Day Range:
$3.26
$3.37
1-Week Range:
$3.195
$3.42
52-Week Range:
$2.705
$4.725
Arbutus Biopharma Corp Stock (ABUS) Company Profile
Name
Arbutus Biopharma Corp
Sector
Industry
Phone
604-419-3200
Address
701 VETERANS CIRCLE, WARMINSTER, PA
Compare ABUS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABUS
Arbutus Biopharma Corp
|
3.28 | 632.04M | 12.99M | -74.39M | -78.92M | -0.44 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Arbutus Biopharma Corp Stock (ABUS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-02-22 | Upgrade | Jefferies | Hold → Buy |
| Feb-25-21 | Initiated | Jefferies | Hold |
| Dec-17-20 | Initiated | H.C. Wainwright | Buy |
| Jul-27-20 | Resumed | JMP Securities | Mkt Outperform |
| Jul-24-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-19-20 | Upgrade | Wedbush | Neutral → Outperform |
| Mar-06-20 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Feb-20-20 | Initiated | Robert W. Baird | Outperform |
| Feb-05-20 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Oct-07-19 | Reiterated | B. Riley FBR | Buy |
| Oct-04-19 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-16-18 | Upgrade | B. Riley FBR | Neutral → Buy |
| Oct-15-18 | Upgrade | Wedbush | Underperform → Neutral |
| Oct-12-18 | Reiterated | Chardan Capital Markets | Buy |
| Jul-06-18 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| Mar-19-18 | Resumed | Chardan Capital Markets | Buy |
| Mar-19-18 | Downgrade | Wedbush | Outperform → Neutral |
| Jan-05-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Apr-04-17 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Feb-01-17 | Reiterated | Wedbush | Outperform |
| Dec-13-16 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Nov-30-16 | Upgrade | Chardan Capital Markets | Neutral → Buy |
View All
Arbutus Biopharma Corp Stock (ABUS) Latest News
Is now a turning point for Arbutus Biopharma CorporationWeekly Portfolio Update with ROI Focus - Newser
Technical analysis overview for Arbutus Biopharma Corporation stockFree Buy Low Sell High Stock Watch - Newser
Arbutus Biopharma Corporation Recovery Hinges on Volume BreakoutSecure Return Focused Investment Plan Released - metal.it
What data driven models say about Arbutus Biopharma Corporation’s futureStrategy Builder for Growth Focused Traders - Newser
Published on: 2025-07-30 00:59:28 - Newser
Will breakout in Arbutus Biopharma Corporation lead to full recoveryFree Reliable Chart-Based Trade Entries - Newser
When is the best time to buy Arbutus Biopharma Corporation stockFree Community Shared Smart Money Signals - Newser
What risks could impact Arbutus Biopharma Corporation stock performanceDaily Momentum Screener With Alerts Launched - metal.it
Published on: 2025-07-28 23:59:46 - beatles.ru
Applying big data sentiment scoring on Arbutus Biopharma CorporationFree High Yield Stock Screening Results - Newser
Does Arbutus Biopharma Corporation stock perform well during market downturnsRapid market gains - jammulinksnews.com
When is Arbutus Biopharma Corporation stock expected to show significant growthConsistent triple returns - jammulinksnews.com
How strong is Arbutus Biopharma Corporation company’s balance sheetInvest in stocks with strong fundamentals - jammulinksnews.com
What institutional investors are buying Arbutus Biopharma Corporation stockDiscover stocks with massive upside potential - jammulinksnews.com
Published on: 2025-07-28 03:47:36 - jammulinksnews.com
Is Arbutus Biopharma Corporation Stock a Smart Buy in 2025 Investment Analysis InsideVerified Return Tips - Newser
How Arbutus Biopharma Corporation stock performs during market volatilityFree Stock Investment Growth Plan - Newser
Is Arbutus Biopharma Corporation a good long term investmentMassive wealth growth - PrintWeekIndia
What analysts say about Arbutus Biopharma Corporation stockSuperior returns - jammulinksnews.com
Arbutus Biopharma Corporation (NASDAQ:ABUS) Position Cut by Teacher Retirement System of Texas - Defense World
What drives Arbutus Biopharma Corporation stock priceSuperior stock growth - Autocar Professional
Arbutus Biopharma Corporation Stock Analysis and ForecastDynamic profit opportunities - jammulinksnews.com
Why Arbutus Biopharma Corporation stock attracts strong analyst attentionBreakout Confirmation Tool - Newser
What makes Arbutus Biopharma Corporation stock price move sharplyFree Deep Market Trend Analysis - Newser
Warminster Biopharma Firm Ends $285M Licensing Deal with Chinese Company - BUCKSCO.Today
Arbutus Biopharma (ABUS) Reacquires China Rights to Lead Drug | - GuruFocus
Arbutus reacquires China rights to imdusiran after Qilu partnership ends - Investing.com
Arbutus Biopharma Co. (NASDAQ:ABUS) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Ameriprise Financial Inc. Makes New $62,000 Investment in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Bank of America Corp DE Acquires 171,906 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Millennium Management LLC Purchases 92,068 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Deutsche Bank AG Buys 75,212 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Northern Trust Corp Has $4.35 Million Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Arbutus Biopharma Reports Q1 2025 Results, Clinical Developments, and Legal Progress - MyChesCo
Mercer Global Advisors Inc. ADV Makes New Investment in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Arbutus Biopharma Co. (NASDAQ:ABUS) Stake Boosted by Price T Rowe Associates Inc. MD - Defense World
Arbutus: Q1 Earnings Snapshot - CT Insider
Arbutus Biopharma Corp Reports Q1 2025 Earnings: Revenue at $1.8 Million, EPS Misses Estimate with $0.13 Loss - GuruFocus
Arbutus Biopharma earnings missed by $0.03, revenue fell short of estimates - Investing.com Canada
Arbutus Biopharma (ABUS) Reports Mixed Q1 Results - GuruFocus
Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Arbutus (ABUS) Reports Lower Q1 Revenue Amid Promising Treatment Progress | ABUS Stock News - GuruFocus
Arbutus Biopharma Corp Stock (ABUS) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):